-
公开(公告)号:US20230039553A1
公开(公告)日:2023-02-09
申请号:US17243911
申请日:2021-04-29
发明人: Mark J. Bartlett , Gregory F. Chin , Michael O. Clarke , Jennifer L. Cosman , Deeba Ensan , Bindu Goyal , Stephen Ho , Hon C. Hui , Richard L. Mackman , Michael R. Mish , Scott D. Schroeder , Nathan D. Shapiro , Dustin S. Siegel , Doris T. Tang , Hai Yang
IPC分类号: C07D487/04 , C07D519/00 , A61K45/06 , C07K16/28
摘要: The present disclosure provides pyrimidine dione compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors. The compounds can be used alone or in combination with other anti-cancer agents.
-
公开(公告)号:US20210171500A1
公开(公告)日:2021-06-10
申请号:US17096150
申请日:2020-11-12
发明人: Brian P. Bestvater , Zhimin Du , Julie Farand , Gregory Notte , Barton W. Phillips , Doris T. Tang , Chandrasekar Venkataramani , Peiyuan Wang , Kin S. Yang , Anna Zagorska
IPC分类号: C07D401/14 , C07D401/04 , C07D417/14 , C07D409/14 , C07D413/14 , C07D405/14
摘要: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH).
-
公开(公告)号:US11584738B2
公开(公告)日:2023-02-21
申请号:US17319507
申请日:2021-05-13
发明人: Brian P. Bestvater , Zhimin Du , Julie Farand , Joshua A. Kaplan , Barton W. Phillips , Doris T. Tang , Chandrasekar Venkataramani , Peiyuan Wang , Kin S. Yang , Anna Zagorska
IPC分类号: C07D401/14 , C07D409/14 , C07D405/14
摘要: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD), or chronic kidney disease (CKD).
-
公开(公告)号:US20230012262A1
公开(公告)日:2023-01-12
申请号:US17319507
申请日:2021-05-13
发明人: Brian P. Bestvater , Zhimin Du , Julie Farand , Joshua A. Kaplan , Barton W. Phillips , Doris T. Tang , Chandrasekar Venkataramani , Peiyuan Wang , Kin S. Yang , Anna Zagorska
IPC分类号: C07D401/14 , C07D405/14 , C07D409/14
摘要: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD), or chronic kidney disease (CKD).
-
公开(公告)号:US11548871B2
公开(公告)日:2023-01-10
申请号:US17096150
申请日:2020-11-12
发明人: Brian P. Bestvater , Zhimin Du , Julie Farand , Gregory Notte , Barton W. Phillips , Doris T. Tang , Chandrasekar Venkataramani , Peiyuan Wang , Kin S. Yang , Anna Zagorska
IPC分类号: C07D498/04 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D413/04 , A61K31/65 , A61P11/00 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14
摘要: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH).
-
公开(公告)号:US20210380561A1
公开(公告)日:2021-12-09
申请号:US17319471
申请日:2021-05-13
IPC分类号: C07D403/10 , C07D401/10 , C07D413/10 , C07D498/04 , C07D401/14 , C07D413/14
摘要: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non alcoholic steatohepatitis (NASH).
-
-
-
-
-